1373046-71-9Relevant academic research and scientific papers
BENZAMIDE TRPA1 ANTAGONISTS
-
Page/Page column 64, (2014/12/12)
Compounds of formula I, pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R, X, Y, Z, n and A are as defined in the specification, as well as pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
TRPA1 ANTAGONIST COMPOUNDS
-
Page/Page column 35, (2014/12/12)
Compounds of Formula (I), pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R1, R2, R3, X, Yn and A are as defined in the specification, as well as pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
TRPA1 RECEPTOR ANTAGONIST
-
Page/Page column 16, (2012/05/04)
A compound of Formula (I), pharmaceutically acceptable salts thereof, enantiomers, or mixtures thereof: pharmaceutical compositions containing said compounds, enantiomers or mixtures, processes for making said compounds, enantiomers or mixtures, the use of said compounds, enantiomers or mixtures, and medicaments containing the same for treatment of pain and other conditions, and methods of treating pain and other conditions with the same.
N-1-Alkyl-2-oxo-2-aryl amides as novel antagonists of the TRPA1 receptor
Vallin, Karl S.A.,Sterky, Karin J.,Nyman, Eva,Bernstroem, Jenny,From, Rebecka,Linde, Christian,Minidis, Alexander B.E.,Nolting, Andreas,Naerhi, Katja,Santangelo, Ellen M.,Sehgelmeble, Fernando W.,Sohn, Daniel,Strindlund, Jennie,Weigelt, Dirk
supporting information; experimental part, p. 5485 - 5492 (2012/09/22)
A series of potent antagonists of the ion channel transient receptor potential A1 (TRPA1) was developed by modifying lead structure 16 that was discovered by high-throughput screening. Based on lead compound 16, a SAR was established, showing a narrow region at the nitro-aromatic R1 moiety and at the warhead, while the R2 side had a much wider scope including ureas and carbamates. Compound 16 inhibits Ca2+-activated TRPA1 currents reversibly in whole cell patch clamp experiments, indicating that under in vivo conditions, it does not react covalently, despite its potentially electrophilic ketone.
